The optimal treatment of anaplastic gliomas is controversial. Options for treatment include radiation, chemotherapy or a combination of modalities. This article describes how treatment algorithms for anaplastic gliomas have evolved…
Low-grade gliomas are uncommon tumors whose optimal management remains to be determined. Although well-designed clinical trials have been mounted to address certain aspects of postoperative radiotherapeutic management, additional studies are…
The diverse medical and neurologic complications of central nervous system (CNS) neoplasms or their treatment cause significant morbidity and mortality. Thus, their recognition and appropriate management by all members of…
In the United States, approximately 65,000 people are diagnosed with primary brain tumors each year, with an incidence of 19.3 cases per 100,000 person-years. These numbers represent a wide spectrum…
The clinical manifestations of intracranial tumors are usually referable to the anatomic area of the brain involved or adjacent structures. Some anatomic regions may allow a tumor to reach substantial…
Contemporary neuropathology plays a key role in the multidisciplinary management of brain tumor patients, in part due to increased supplementation of histopathological assessments by molecular diagnostic tests involving brain tumor…
Jill Lacy, MD, Guest Editor Joachim M. Baehring, MD, DSc, Guest Editor Related posts: Low-Grade Gliomas Glioblastoma Multiforme Meningiomas, Nerve Sheath Tumors, and Pituitary Tumors Role of Neurosurgery and Radiation…
The clinical presentation of mastocytosis is diverse, and patients may not fit the classical description. Diagnosis requires a bone marrow examination, including immunohistochemical stains for mast cell tryptase or CD117….
Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are dominated by a high risk of thrombosis and a late risk…
The development of JAK2 inhibitors followed the discovery of activating mutation of JAK2 (JAK2V617F) in patients with classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPN). It is now known that mutations activating…
